Healthtech Series A Investors & VC Firms

2309 firms in this list, with a median first check of $500K. 550 of them lead rounds. Generated from verified public data and updated continuously.

Fund	FoxScore	HQ	Invests	Stage	Check	CRM
GO Golden Palm BASDCEBD5 people · Leads rounds	88🔒	—	GH	Pre-Seed–Series A	$50K – $5M	+ Add to CRM
GR GR Capital DLMFSKAL8 people · Follows rounds	88🔒	London	GB	Series A–Growth	$3.2M – $10.8M	+ Add to CRM
BL Blue Bear Ventures DGPSACMA6 people · Follows rounds	88🔒	Berkeley	US	Pre-Seed–Series A	$100K – $400K	+ Add to CRM
I& i&i Biotech Fund KKMKIVTM9 people	88🔒	Luxembourg	LU	Pre-Seed–Series A	$150K – $2M	+ Add to CRM
IN Innovation Nest WDDDGKKF9 people	88🔒	Kraków	PL	Seed–Series A	$108K – $1.1M	+ Add to CRM
YZ YZR Capital MFHEMSUK12 people · Leads rounds	88🔒	Munich	DE	Pre-Seed–Growth	—	+ Add to CRM
53 53 Stations JPKGCOAD11 people	88🔒	Chicago	US	Pre-Seed–Series A	—	+ Add to CRM
IN Infinitas Capital RLRHSLAC17 people	88🔒	—		Pre-Seed–Late Stage	—	+ Add to CRM
SU Sumisho Venture Partners YTHY山英HT14 people	88🔒	Tokyo	JP	Seed–Growth	—	+ Add to CRM
TI TIBAS Ventures ESEYMKEY8 people	88🔒	Amsterdam	NL	Pre-Seed–Growth	—	+ Add to CRM
SE SEEDS Capital JSNK2 people · Follows rounds	88🔒	Singapore	SG	Pre-Seed–Series A	$250K – $12M	+ Add to CRM
DE Delft Enterprises B.V. RGJMEVJP16 people	88🔒	Delft	NL	Pre-Seed–Series A	—	+ Add to CRM
EA Easton Capital CHFGJFKL7 people	88🔒	New York	US	Seed–Series B	$10M – $20M	+ Add to CRM
FI Firstrock Capital ABESHBJM4 people · Follows rounds	88🔒	Miami	US	Seed–Series A	$50K – $5M	+ Add to CRM
IN Innoangel ZQZX周祝4 people · Follows rounds	88🔒	Beijing	CN	Pre-Seed–Series A	$1.4M	+ Add to CRM
RI Rittenhouse Ventures SRBLDNSR7 people · Leads rounds	88🔒	Philadelphia	US	Seed–Growth	$1M – $3M	+ Add to CRM
4I 4impact capital ANPWYVLE9 people · Leads rounds	88🔒	The Hague	NL	Seed–Series A	—	+ Add to CRM
CU CU Healthcare Innovation Fund KMSLGBGL6 people	88🔒	Aurora	US	Seed–Series A	—	+ Add to CRM
SE Selva Ventures KDDWMGRP6 people · Leads rounds	88🔒	Los Angeles	US	Seed–Series A	$100K – $5M	+ Add to CRM
SO Solasta Ventures MJBCDYKG6 people	88🔒	Boston	US	Seed–Series B	—	+ Add to CRM
SO Source Ventures MCVMHL3 people	88🔒	—		Seed–Series A	$108K	+ Add to CRM
TB TBT	88🔒	Seoul	KR	Pre-Seed–Late Stage	—	+ Add to CRM
VI Visionary Ventures GHDGPSBC9 people	88🔒	Newport Beach	US	Series A–Growth	$5M – $15M	+ Add to CRM
CR Cross-Border Impact Ventures ATDPMDIG11 people	88🔒	Toronto	CA	Series A–Series B	$2M – $10M	+ Add to CRM

Golden Palm

Pre-Seed–Series A$50K – $5M

BASDCEBD5 people

GR Capital

LondonSeries A–Growth$3.2M – $10.8M

DLMFSKAL8 people

Blue Bear Ventures

BerkeleyPre-Seed–Series A$100K – $400K

DGPSACMA6 people

i&i Biotech Fund

LuxembourgPre-Seed–Series A$150K – $2M

KKMKIVTM9 people

Innovation Nest

KrakówSeed–Series A$108K – $1.1M

WDDDGKKF9 people

YZR Capital

MunichPre-Seed–Growth

MFHEMSUK12 people

53 Stations

ChicagoPre-Seed–Series A

JPKGCOAD11 people

Infinitas Capital

Pre-Seed–Late Stage

RLRHSLAC17 people

Sumisho Venture Partners

TokyoSeed–Growth

YTHY山英HT14 people

TIBAS Ventures

AmsterdamPre-Seed–Growth

ESEYMKEY8 people

SEEDS Capital

SingaporePre-Seed–Series A$250K – $12M

JSNK2 people

Delft Enterprises B.V.

DelftPre-Seed–Series A

RGJMEVJP16 people

Easton Capital

New YorkSeed–Series B$10M – $20M

CHFGJFKL7 people

Firstrock Capital

MiamiSeed–Series A$50K – $5M

ABESHBJM4 people

Innoangel

BeijingPre-Seed–Series A$1.4M

ZQZX周祝4 people

Rittenhouse Ventures

PhiladelphiaSeed–Growth$1M – $3M

SRBLDNSR7 people

4impact capital

The HagueSeed–Series A

ANPWYVLE9 people

CU Healthcare Innovation Fund

AuroraSeed–Series A

KMSLGBGL6 people

Selva Ventures

Los AngelesSeed–Series A$100K – $5M

KDDWMGRP6 people

Solasta Ventures

BostonSeed–Series B

MJBCDYKG6 people

Source Ventures

Seed–Series A$108K

MCVMHL3 people

TBT

SeoulPre-Seed–Late Stage

Visionary Ventures

Newport BeachSeries A–Growth$5M – $15M

GHDGPSBC9 people

Cross-Border Impact Ventures

TorontoSeries A–Series B$2M – $10M

ATDPMDIG11 people

Data sourced from public filings and firms' own websites — see our methodology.